Literature DB >> 9822059

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

J Hirsh1, T E Warkentin, R Raschke, C Granger, E M Ohman, J E Dalen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9822059     DOI： 10.1378/chest.114.5_supplement.489s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  69 in total

Review 1.  New antithrombotic and antiplatelet treatment.

Authors:  K L Neuhaus
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

Review 2.  Acute pulmonary embolism 2: treatment.

Authors:  M Riedel
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

3.  Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P.

Authors:  M Thanou; J C Verhoef; M T Nihot; J H Verheijden; H E Junginger
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

4.  Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins.

Authors:  G J Merli; G J Vanscoy; T L Rihn; J B Groce; W McCormick
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 5.  Drug-induced thrombocytopenia in the coronary care unit.

Authors:  N M Patnode; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

6.  Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

Authors:  Erin E Soule; Kristin M Bompiani; Rebecca S Woodruff; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2015-11-19       Impact factor: 5.486

7.  Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors:  Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal:  ACS Med Chem Lett       Date:  2019-05-08       Impact factor: 4.345

Review 8.  Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.

Authors:  Nick Bosanquet; Bengt Jönsson; Keith A A Fox
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?

Authors:  Wesley D Kufel; Robert W Seabury; William Darko; Luke A Probst; Christopher D Miller
Journal:  Hosp Pharm       Date:  2017-03

10.  Does a delay in performing an activated clotting (ACT) test really matter? A study in nonheparinized blood and a single ACT machine.

Authors:  Bridget M Philip; John G Brock-Utne; Harry J M Lemmens; Richard A Jaffe; Paul E Shuttleworth
Journal:  J Extra Corpor Technol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.